Polaris Group
20 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC) (NCT05712694) | Polaris Group | 2023-11-29 |
| Study of ADI-PEG 20 Versus Placebo in Subjects With NASH (NCT05842512) | Polaris Group | 2023-09-13 |
| Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia (NCT05001828) | Polaris Group | 2022-04-05 |
| Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma (NCT05317819) | Polaris Group | 2022-03-14 |
| ADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects With Glioblastoma Multiforme (NCT04587830) | Polaris Group | 2020-09-14 |
Track Polaris Group automatically
Every clearance here is in the API, with alerts when new ones post.